These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance].
    Author: Chen WY, Mao WM, Zhao L, Chen GP, Shu Y, Shen YF, Zhu XH, Xia Y.
    Journal: Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):738-40. PubMed ID: 16483485.
    Abstract:
    OBJECTIVE: To study the expression and clinical significance of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers. METHODS: The expression of P-gp, GST-pi and Topo II alpha in 83 cases with gastric or colorectal cancer were examined by immunohistochemistry S-P. RESULTS: The positive expression rates of P-gp, GST-pi, Topo II alpha in normal tissue and gastric and colorectal cancers were 69.9%, 65.1%, 50.6% and 83.1%, 85.5%, 45.8%, respectively. The positive rates of P-gp and GST-pi in gastric and colorectal cancer were significantly higher than those in normal gastric and colorectal tissue (P < 0.05). The expression of Topo II alpha in poorly differentiated cancers was significantly higher than that in well-and moderately differentiated cancers. There was no correlation between other items and clinicopathological parameters (P > 0.05). CONCLUSION: P-gp, GST-pi and Topo II alpha play important role in multidrug resistance. Their mechanisms of drug resistance were different. The detection of expression of P-gp, GST-pi and Topo II alpha has an important guiding significance in chemotherapy for gastric and colorectal cancers.
    [Abstract] [Full Text] [Related] [New Search]